FNCH Finch Therapeutics Group Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FNCH

Price (delayed)

$2.25

Market cap

$3.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$46.59

Enterprise value

$8.61M

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete ...

Highlights
FNCH's debt is down by 42% year-on-year and by 2.1% since the previous quarter
FNCH's EPS is up by 35% YoY and by 26% QoQ
The company's revenue has shrunk by 88% YoY and by 7% QoQ
FNCH's gross profit has dropped by 88% year-on-year and by 7% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://finchtherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of FNCH
Market
Shares outstanding
1.61M
Market cap
$3.61M
Enterprise value
$8.61M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.16
Price to sales (P/S)
33.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
80.51
Earnings
Revenue
$107,000
EBIT
-$79.79M
EBITDA
-$75.6M
Free cash flow
-$30.18M
Per share
EPS
-$46.59
Free cash flow per share
-$18.81
Book value per share
$14.25
Revenue per share
$0.07
TBVPS
$34.51
Balance sheet
Total assets
$55.37M
Total liabilities
$32.49M
Debt
$30.13M
Equity
$22.89M
Working capital
$21.76M
Liquidity
Debt to equity
1.32
Current ratio
6.33
Quick ratio
6.15
Net debt/EBITDA
-0.07
Margins
EBITDA margin
-70,656.1%
Gross margin
100%
Net margin
-69,863.6%
Operating margin
-78,374.8%
Efficiency
Return on assets
-114.7%
Return on equity
-273%
Return on invested capital
-140.3%
Return on capital employed
-155.6%
Return on sales
-74,565.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FNCH stock price

How has the Finch Therapeutics Group stock price performed over time
Intraday
-9.64%
1 week
-1.32%
1 month
-4.66%
1 year
-99.32%
YTD
-37.67%
QTD
-13.46%

Financial performance

How have Finch Therapeutics Group's revenue and profit performed over time
Revenue
$107,000
Gross profit
$107,000
Operating income
-$83.86M
Net income
-$74.75M
Gross margin
100%
Net margin
-69,863.6%
The company's revenue has shrunk by 88% YoY and by 7% QoQ
FNCH's gross profit has dropped by 88% year-on-year and by 7% since the previous quarter
FNCH's net income is up by 35% YoY and by 25% QoQ
FNCH's operating income is up by 27% year-on-year and by 23% since the previous quarter

Growth

What is Finch Therapeutics Group's growth rate over time

Valuation

What is Finch Therapeutics Group stock price valuation
P/E
N/A
P/B
0.16
P/S
33.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
80.51
FNCH's EPS is up by 35% YoY and by 26% QoQ
Finch Therapeutics Group's equity has shrunk by 76% YoY and by 11% QoQ
FNCH's price to book (P/B) is 58% lower than its last 4 quarters average of 0.4
The company's revenue has shrunk by 88% YoY and by 7% QoQ
The stock's price to sales (P/S) is 33% less than its last 4 quarters average of 52.8

Efficiency

How efficient is Finch Therapeutics Group business performance
Finch Therapeutics Group's return on assets has shrunk by 96% YoY and by 5% QoQ
The ROIC is down by 48% year-on-year
FNCH's ROE is down by 24% from the previous quarter
FNCH's ROS is up by 19% QoQ

Dividends

What is FNCH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FNCH.

Financial health

How did Finch Therapeutics Group financials performed over time
Finch Therapeutics Group's total assets is 70% higher than its total liabilities
Finch Therapeutics Group's total assets has shrunk by 66% YoY and by 7% QoQ
Finch Therapeutics Group's total liabilities has shrunk by 52% YoY and by 3.5% QoQ
FNCH's debt is 32% greater than its equity
The debt to equity has surged by 140% year-on-year and by 11% since the previous quarter
Finch Therapeutics Group's equity has shrunk by 76% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.